Quick Answer
MAXCYTE, INC. reported Cash And Cash Equivalents At Carrying Value of $20.07 million for the year ending 2025.
- MAXCYTE, INC. showed a decrease of -28.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from MAXCYTE, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $37.42 million | Q3 2021: $58.97 million | Q1 2022: $239.78 million | Q2 2022: $109.17 million | Q3 2022: $43.02 million | Q1 2023: $37.83 million | Q2 2023: $54.56 million | Q3 2023: $49.17 million | Q1 2024: $22.25 million | Q2 2024: $37.51 million | Q3 2024: $36.96 million | Q1 2025: $23.39 million | Q2 2025: $15.23 million | Q3 2025: $12.97 million.
- Over the full 6 years of available data (2020 to 2025), MAXCYTE, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 7.0%.
- Historical annual values: Fiscal year 2025: $20.07 million | Fiscal year 2024: $27.88 million | Fiscal year 2023: $46.51 million | Fiscal year 2022: $11.07 million | Fiscal year 2021: $47.78 million | Fiscal year 2020: $18.76 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: